OBJECTIVES: Bioresorbable stents are novel devices designed to overcome the long-term limitations of permanent stent implantation. The main aim of this study was to perform cost-effectiveness analysis of using Absorb bioresorbable vascular scaffold (BVS) system for patients with STEMI.

METHODS: Analysis of the published clinical trials was conducted to evaluate efficacy and safety of using Absorb BVS system for patients with STEMI. Taking into account the hypothesis of superior effectiveness of Absorb BVS system for patients with STEMI for pharmacoeconomic analysis was chosen “cost-effectiveness” analysis. MS Excel based model was performed to asses 2 strategies: strategy 1- patients with primary percutaneous coronary intervention (PPCI) with Absorb BVS system; strategy 2 - patients received thrombolytic therapy in the hospital. The 1 LYG and 1 surviving patient were included into the model as the effectiveness criteria. Direct costs included emergency, inpatient and outpatient treatment, rehabilitation and cost of PPCI with Absorb BVS system. All the direct costs were calculated from the Russian healthcare system perspective.

RESULTS: According to published trials the using of Absorb BVS system for patients with STEMI did not lead to different rates of composite patient-oriented and device-oriented adverse events. Strategy 1 has a higher efficiency - the proportion of survivors at 1 year will be the maximum – 92.7%, as well as the LYG – 5.4. Application of strategy 1reduces the total cost of reperfusion therapy for all patients with STEMI, the difference amounted to $273,537. According to the CER for 1 LYG and for 1 surviving patient was optimal strategy 1, the difference amounted to $50 and $297, respectively (rate for June 2017).

CONCLUSIONS: Using Absorb BVS system during reperfusion in patients with STEMI was effective and economically justified treatment option.